The External Automatic Glaucoma Laser (EAGLE) device has been developed and patented by BELKIN Laser (partner BEL) with the vision of providing a world-wide , cost-effective solution that enables an accessible first-line choice of treatment for glaucoma by an innovative one-second automatic laser treatment for the benefit of both ophthalmologists and patients. This novel, non-contact method directs the beams deep into the limbus (the border between the colored and the white parts of the eye), a location which overlies the target tissue (trabecular meshwork).
The instrument delivers 100-120 laser applications automatically and simultaneously. This will enable treatment by this novel cost-effective device to be completed in about one second in an automatic mode implementing image-acquisition technology, and could be performed by any ophthalmologist, not only glaucoma specialist. Thus, the clinical use of EAGLE will allow the world’s 212,000 eye doctors to offer laser therapy as a primary treatment for glaucoma, thereby overcoming the grave availability and compliance problems associated with eye drop therapy. The innovative technology provides a solution not only for Open Angel Glaucoma (OAG, 74% of total glaucoma cases) but may also serve as an exclusive solution for Angle Closure Glaucoma (ACG, ~26%). ACG is most common among East Asian and Indian populations and is the leading cause of irreversible blindness in China.